Discontinuation due to pregnancy (750 days) · patients with Immediate insertion Post abortion
TCu 220C showed no clear difference in discontinuation due to pregnancy (750 days) compared with copper 7 (moderate certainty).
1 finding from 1 review
Discontinuation due to expulsion (750 days) · patients with Immediate insertion Post abortion
TCu 220C showed no clear difference in discontinuation due to expulsion (750 days) compared with copper 7 (moderate certainty).
1 finding from 1 review
Discontinuation due to pelvic inflammation · patients with Immediate insertion Post abortion
1 finding from 1 review
Discontinuation due to perforation · patients with Immediate insertion Post abortion
1 finding from 1 review
Discontinuation due to perforation · patients with Immediate insertion Post abortion
TCu 220C showed no clear difference in discontinuation due to perforation (750 days) Tietze‐Potter gross… compared with lippes Loop (moderate certainty).
1 finding from 1 review
Discontinuation due to pelvic inflammation · patients with Immediate insertion Post abortion
TCu 220C showed no clear difference in discontinuation due to pelvic inflammatory disease (750 days) compared with lippes Loop (moderate certainty).
1 finding from 1 review
Discontinuation due to pregnancy (750 days) · patients with Immediate insertion Post abortion
TCu 220C probably leads to lower discontinuation rate due to pregnancy (750days) compared with lippes Loop (moderate certainty).
1 finding from 1 review
Discontinuation due to expulsion (750 days) · patients with Immediate insertion Post abortion
TCu 220C probably leads to lower discontinuation rate due to expulsion (750 days) Tietze‐Potter gross… compared with lippes Loop (moderate certainty).
1 finding from 1 review
Continuation of status requiring a different drug or general anaesthesia · patients with status epilepticus
Lorazepam IV probably leads to lower continuation of status requiring a different drug or general… compared with diazepam IV (moderate certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · people with chronic hepatitis C
Peginterferon plus ribavirin showed no clear difference in adverse events leading to treatment discontinuation compared with non‐pegylated interferon plus ribavirin (low certainty).
1 finding from 1 review
Adverse events: severe adverse events requiring treatment discontinuation ‐ TMP/SMX versus placebo or no treatment Clinical and laboratory criteria and treatment discontinuations · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients
TMP/SMX showed no clear difference in adverse events: severe adverse events requiring treatment… compared with placebo, no treatment or non‐PCP drug (moderate certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · people with chronic hepatitis C
Peginterferon alpha‐2a showed no clear difference in adverse events leading to treatment discontinuation Number of events compared with peginterferon alpha‐2b (low certainty).
1 finding from 1 review
All‐cause treatment discontinuation ‐ desipramine · Children and adolescents with ADHD
1 finding from 1 review
Overall discontinuation ( · patients with managing transfusional iron overload in people with sickle cell disease
Deferasirox may leads to lower discontinuations compared with deferoxamine (low certainty).
1 finding from 1 review
Discontinuation of treatment due to side effects ( · participants with melanoma in situ, including lentigo maligna
Imiquimod 5% cream with tazarotene 0.1% gel showed no clear difference in secondary outcome: Discontinuation of treatment because of harms… compared with imiquimod 5% cream alone (low certainty).
1 finding from 1 review
Adverse events requiring discontinuation of antibiotics · people with cancer who have febrile neutropenia
Oral showed no clear difference in adverse events requiring discontinuation of antibiotics compared with intravenous antibiotic therapy (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy leads to lower discontinuation due to adverse events compared with fixed dose ICS (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy probably leads to higher discontinuation due to adverse events compared with current best practice (moderate certainty).
1 finding from 1 review
Intervention not reported
Discontinuation for adverse events · HIV‐infected adult patients treated with a PI‐containing regimen with undetectable viral load
The intervention showed no clear difference in discontinuation for adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events requiring discontinuation [range of median · patients with APL in first complete remission
The intervention probably leads to lower adverse events requiring discontinuation [range of median (moderate certainty).
1 finding from 1 review
no estimate extracted
906 participants
Moderate